Atossa Genetics Inc. (NASDAQ:ATOS) Receives Average Recommendation of “Hold” from Analysts

Atossa Genetics Inc. (NASDAQ:ATOS) has been assigned a consensus rating of “Hold” from the five analysts that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $36.3333.

Several equities analysts have recently commented on the stock. HC Wainwright boosted their price target on shares of Atossa Genetics to $25.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Weiss Ratings upgraded shares of Atossa Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Finally, Ascendiant Capital Markets lowered their price target on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating on the stock in a report on Friday, April 10th.

Hedge Funds Weigh In On Atossa Genetics

Institutional investors and hedge funds have recently modified their holdings of the stock. Graham Capital Management L.P. grew its holdings in shares of Atossa Genetics by 27.8% during the 4th quarter. Graham Capital Management L.P. now owns 211,369 shares of the company’s stock valued at $125,000 after acquiring an additional 45,923 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of Atossa Genetics by 55.8% in the 3rd quarter. Bank of America Corp DE now owns 155,169 shares of the company’s stock valued at $135,000 after purchasing an additional 55,568 shares during the last quarter. Squarepoint Ops LLC lifted its stake in shares of Atossa Genetics by 39.9% in the 3rd quarter. Squarepoint Ops LLC now owns 253,343 shares of the company’s stock valued at $220,000 after purchasing an additional 72,235 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Atossa Genetics by 1,294.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after purchasing an additional 35,474 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its stake in shares of Atossa Genetics by 357.4% in the 2nd quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock valued at $346,000 after purchasing an additional 325,340 shares during the last quarter. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

Atossa Genetics Stock Up 3.4%

Atossa Genetics stock opened at $5.12 on Thursday. The company’s fifty day simple moving average is $5.29 and its 200-day simple moving average is $7.44. Atossa Genetics has a 12 month low of $3.76 and a 12 month high of $19.35. The stock has a market cap of $44.08 million, a P/E ratio of -1.60 and a beta of 1.25.

Atossa Genetics (NASDAQ:ATOS) last posted its quarterly earnings results on Friday, May 8th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.12). On average, equities research analysts expect that Atossa Genetics will post -4.41 earnings per share for the current fiscal year.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.